Why the study?
What are the pharmacokinetic properties of immediate-release oral fampridine in normal subjects and patients with spinal cord injury?
What are the pharmacokinetic properties of immediate-release oral fampridine in normal subjects and patients with spinal cord injury?
Immediate-release oral fampridine has similar pharmacokinetic profiles in normal subjects and patients with spinal cord injury, with rapid absorption and a half-life of 3 to 4 hours.
Answers are grounded in this paper and cite their sources.
Supports equivalent dosing in SCI patients; confirms no pharmacokinetic differences from healthy controls.
Plasma concentration profiles of the K+ channel-blocking compound Fampridine were obtained from (1) control subjects (n = 6) following oral administration of doses of 10, 15, 20, and 25 mg and (2) patients with spinal cord injury (SCI) (n = 11) following a single oral dose of 10 mg of an immediate-release formulation. Plasma concentrations were determined using a reversed-phase ion-pair high-performance liquid chromatography (HPLC) assay with ultraviolet light detection employing liquid extraction. The drug was rapidly absorbed with a tmax approximately 1 hour for both groups; tmax was independent of dose. Cmax and AUC0-infinity were linearly related to dose, and t 1/2 was 3 to 4 hours for both groups. There were no obvious differences in the (10-mg) plasma concentration profiles between control subjects and SCI patients. The drug was well tolerated, with only mild and transient side effects of light-headedness, dysesthesias, and dizziness.
No takes yet. Share an insight, caveat, or question.
Hayes et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: